Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

[Place of ultrasound in the management of Mayer-Rokitansky-Kuster-Hauser syndrome. Observational study from 2000 to 2017 within university hospital of Strasbourg].

Schwaab T, Bryand A.

Gynecol Obstet Fertil Senol. 2019 Nov;47(11):783-789. doi: 10.1016/j.gofs.2019.07.002. Epub 2019 Jul 5. French.

PMID:
31280033
2.

Tumor-associated macrophage expression of interferon regulatory Factor-8 (IRF8) is a predictor of progression and patient survival in renal cell carcinoma.

Muhitch JB, Hoffend NC, Azabdaftari G, Miller A, Bshara W, Morrison CD, Schwaab T, Abrams SI.

J Immunother Cancer. 2019 Jun 20;7(1):155. doi: 10.1186/s40425-019-0630-0.

3.

Identification and Validation of Radiographic Enhancement for Reliable Differentiation of CD117(+) Benign Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.

Amin J, Xu B, Badkhshan S, Creighton TT, Abbotoy D, Murekeyisoni C, Attwood KM, Schwaab T, Hendler C, Petroziello M, Roche CL, Kauffman EC.

Clin Cancer Res. 2018 Aug 15;24(16):3898-3907. doi: 10.1158/1078-0432.CCR-18-0252. Epub 2018 May 11.

4.

Development of a Patient-Based Model for Estimating Operative Times for Robot-Assisted Radical Prostatectomy.

Huben NB, Hussein AA, May PR, Whittum M, Krasowski C, Ahmed YE, Jing Z, Khan H, Kim HL, Schwaab T, Underwood W, Kauffman EC, Mohler JL, Guru KA.

J Endourol. 2018 Aug;32(8):730-736. doi: 10.1089/end.2018.0249.

5.

A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.

Singh AK, Winslow TB, Kermany MH, Goritz V, Heit L, Miller A, Hoffend NC, Stein LC, Kumaraswamy LK, Warren GW, Bshara W, Odunsi K, Matsuzaki J, Abrams SI, Schwaab T, Muhitch JB.

Clin Cancer Res. 2017 Sep 1;23(17):5055-5065. doi: 10.1158/1078-0432.CCR-16-2946. Epub 2017 Jun 19.

6.

Outcomes of Minimal Invasive vs Open Radical Nephrectomy for the Treatment of Locally Advanced Renal-Cell Carcinoma.

Bragayrac LA, Abbotoy D, Attwood K, Darwiche F, Hoffmeyer J, Kauffman EC, Schwaab T.

J Endourol. 2016 Aug;30(8):871-6. doi: 10.1089/end.2016.0082. Epub 2016 Jun 17.

PMID:
27203682
7.

Minimally invasive cytoreductive nephrectomy: a multi-institutional experience.

Nunez Bragayrac L, Hoffmeyer J, Abbotoy D, Attwood K, Kauffman E, Spiess P, Wagner A, Schwaab T.

World J Urol. 2016 Dec;34(12):1651-1656. Epub 2016 Apr 15.

PMID:
27084776
8.

Incidence of Clear Cell Papillary Renal Cell Carcinoma in Low-Grade Renal Cell Carcinoma Cases: A 12-Year Retrospective Clinicopathologic Study From a Single Cancer Center.

Gill S, Kauffman EC, Kandel S, George S, Schwaab T, Xu B.

Int J Surg Pathol. 2016 May;24(3):207-12. doi: 10.1177/1066896915613432. Epub 2015 Oct 27.

PMID:
26510859
9.

Early identification of asymptomatic brain metastases from renal cell carcinoma.

Hanzly M, Abbotoy D, Creighton T, Diorio G, Mehedint D, Murekeyisoni C, Attwood K, Kauffman E, Fabiano AJ, Schwaab T.

Clin Exp Metastasis. 2015 Dec;32(8):783-8. doi: 10.1007/s10585-015-9748-8. Epub 2015 Oct 7.

PMID:
26445847
10.

Oncological control associated with surgical resection of isolated retroperitoneal lymph node recurrence of renal cell carcinoma.

Russell CM, Lue K, Fisher J, Kassouf W, Schwaab T, Sexton WJ, Tanguay S, Psutka SP, Thompson RH, Leibovich BC, Hanzly MI, Spiess PE, Boorjian SA.

BJU Int. 2016 Jun;117(6B):E60-6. doi: 10.1111/bju.13212. Epub 2015 Jul 18.

11.

Comparative Analysis of Smoking as a Risk Factor among Renal Cell Carcinoma Histological Subtypes.

Patel NH, Attwood KM, Hanzly M, Creighton TT, Mehedint DC, Schwaab T, Kauffman EC.

J Urol. 2015 Sep;194(3):640-6. doi: 10.1016/j.juro.2015.03.125. Epub 2015 Apr 18.

PMID:
25896558
12.

Cancer control of partial nephrectomy for high-risk localized renal cell carcinoma: population-based and single-institutional analysis.

O'Malley RL, Hayn MH, Brewer KA, Underwood W 3rd, Hellenthal NJ, Kim HL, Sorokin I, Schwaab T.

World J Urol. 2015 Nov;33(11):1807-14. doi: 10.1007/s00345-015-1538-z. Epub 2015 Mar 25.

PMID:
25805189
13.

High-dose IL-2 for metastatic renal cell carcinoma: can the first antitumor immunotherapy be reinvented?

Muhitch JB, Schwaab T.

Immunotherapy. 2014;6(9):955-8. doi: 10.2217/imt.14.78. No abstract available.

14.

Stereotactic Body Radiotherapy for the Treatment of Renal Tumors.

Hanzly M, Creighton T, Mix M, Zeeck K, Fung-Kee-Fung S, Singh AK, Schwaab T.

Urol Case Rep. 2014 Jun 28;2(5):147-9. doi: 10.1016/j.eucr.2014.05.011. eCollection 2014 Sep.

15.

Learning curves for robot-assisted and laparoscopic partial nephrectomy.

Hanzly M, Frederick A, Creighton T, Atwood K, Mehedint D, Kauffman EC, Kim HL, Schwaab T.

J Endourol. 2015 Mar;29(3):297-303. doi: 10.1089/end.2014.0303. Epub 2014 Oct 21.

PMID:
25111313
16.

High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience.

Hanzly M, Aboumohamed A, Yarlagadda N, Creighton T, Digiorgio L, Fredrick A, Rao G, Mehedint D, George S, Attwood K, Kauffman E, Narashima D, Khushalani NI, Pili R, Schwaab T.

Urology. 2014 May;83(5):1129-34. doi: 10.1016/j.urology.2014.02.005.

PMID:
24767525
17.

Surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort.

Russell CM, Espiritu PN, Kassouf W, Schwaab T, Buethe DD, Dhilon J, Sexton WJ, Poch M, Powsang JM, Tanguay S, Nayan M, Alsaadi H, Hanzly MI, Spiess PE.

J Urol. 2014 Aug;192(2):350-6. doi: 10.1016/j.juro.2014.02.010. Epub 2014 Feb 14.

PMID:
24530987
18.

Gender disparity in kidney cancer treatment: women are more likely to undergo radical excision of a localized renal mass.

O'Malley RL, Underwood W 3rd, Brewer KA, Hayn MH, Kim HL, Mehedint DC, Safwat MW, Huang WC, Schwaab T.

Urology. 2013 Nov;82(5):1065-9.

PMID:
24358483
19.

Gene expression profile of peripheral blood lymphocytes from renal cell carcinoma patients treated with IL-2, interferon-α and dendritic cell vaccine.

Wolf B, Schwarzer A, Côté AL, Hampton TH, Schwaab T, Huarte E, Tomlinson CR, Gui J, Fisher JL, Fadul CE, Hamilton JW, Ernstoff MS.

PLoS One. 2012;7(12):e50221. doi: 10.1371/journal.pone.0050221. Epub 2012 Dec 3.

20.
21.

Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy.

Schwarzer A, Wolf B, Fisher JL, Schwaab T, Olek S, Baron U, Tomlinson CR, Seigne JD, Crosby NA, Gui J, Hampton TH, Fadul CE, Heaney JA, Ernstoff MS.

PLoS One. 2012;7(10):e46600. doi: 10.1371/journal.pone.0046600. Epub 2012 Oct 31.

22.

Safety and outcomes of surgical treatment of renal cell carcinoma in the elderly.

O'Malley RL, Hayn MH, Hellenthal NJ, Kim HL, Underwood W 3rd, Schwaab T.

Can J Urol. 2012 Feb;19(1):6111-7.

PMID:
22316513
23.

Perioperative and renal function outcomes of minimally invasive partial nephrectomy for T1b and T2a kidney tumors.

Brewer K, O'Malley RL, Hayn M, Safwat MW, Kim H, Underwood W 3rd, Schwaab T.

J Endourol. 2012 Mar;26(3):244-8. doi: 10.1089/end.2011.0384. Epub 2012 Jan 4.

PMID:
22192099
24.

Synthesis and characterization of a novel tetranuclear 5f compound: a new synthon for exploring U(IV) chemistry.

Newell BS, Schwaab TC, Shores MP.

Inorg Chem. 2011 Dec 5;50(23):12108-15. doi: 10.1021/ic201670z. Epub 2011 Oct 28.

PMID:
22034829
25.

Therapeutic vaccines in renal cell carcinoma.

Schwaab T, Ernstoff MS.

Therapy. 2011 Jul;4(8):369-377.

26.

Provenge: combating prostate cancer with a vengeance?

Schwaab T, Pili R.

Expert Rev Vaccines. 2011 Aug;10(8):1113-4. doi: 10.1586/erv.11.85. No abstract available.

PMID:
21854304
27.

Impact of cytoreductive nephrectomy on eligibility for systemic treatment and effects on survival: are surgical complications or disease related factors responsible?

O'Malley RL, Brewer KA, Hayn MH, Kim HL, Underwood W 3rd, Pili R, Schwaab T.

Urology. 2011 Sep;78(3):595-600. doi: 10.1016/j.urology.2011.03.009. Epub 2011 Jul 20.

PMID:
21777963
28.

Is there a role for partial nephrectomy in patients with metastatic renal cell carcinoma?

Hellenthal NJ, Mansour AM, Hayn MH, Schwaab T.

Urol Oncol. 2013 Jan;31(1):36-41. doi: 10.1016/j.urolonc.2010.08.026. Epub 2011 Mar 10.

PMID:
21396834
29.

Editorial comment for San Francisco et al.

Kowalik T, Schwaab T.

J Endourol. 2011 Feb;25(2):308-9. doi: 10.1089/end.2010.0527. No abstract available.

PMID:
21351842
30.
31.

Renal cell carcinoma in octogenarians: nephron sparing surgery should remain the standard of care.

Hellenthal NJ, Mansour AM, Hayn MH, Schwaab T.

J Urol. 2011 Feb;185(2):415-20. doi: 10.1016/j.juro.2010.09.071. Epub 2010 Dec 17.

PMID:
21167523
32.

RENAL nephrometry score predicts surgical outcomes of laparoscopic partial nephrectomy.

Hayn MH, Schwaab T, Underwood W, Kim HL.

BJU Int. 2011 Sep;108(6):876-81. doi: 10.1111/j.1464-410X.2010.09940.x. Epub 2010 Dec 16.

33.

Clinical and immunologic effects of intranodal autologous tumor lysate-dendritic cell vaccine with Aldesleukin (Interleukin 2) and IFN-{alpha}2a therapy in metastatic renal cell carcinoma patients.

Schwaab T, Schwarzer A, Wolf B, Crocenzi TS, Seigne JD, Crosby NA, Cole BF, Fisher JL, Uhlenhake JC, Mellinger D, Foster C, Szczepiorkowski ZM, Webber SM, Schned AR, Harris RD, Barth RJ Jr, Heaney JA, Noelle RJ, Ernstoff MS.

Clin Cancer Res. 2009 Aug 1;15(15):4986-92. doi: 10.1158/1078-0432.CCR-08-3240. Epub 2009 Jul 21.

34.

Protein isolation from ear wax made easy.

Schwaab M, Hansen S, Gurr A, Schwaab T, Minovi A, Sudhoff H, Dazert S.

Eur Arch Otorhinolaryngol. 2009 Nov;266(11):1699-702. doi: 10.1007/s00405-009-0960-5. Epub 2009 Apr 4.

PMID:
19347346
35.

Dye dilution proliferation assay: application of the DDPA to identify tumor-specific T cell precursor frequencies in clinical trials.

Schwaab T, Fisher JL, Meehan KR, Fadul CE, Givan AL, Ernstoff MS.

Immunol Invest. 2007;36(5-6):649-64.

PMID:
18161523
36.

Tumor-related immunity in prostate cancer patients treated with human recombinant granulocyte monocyte-colony stimulating factor (GM-CSF).

Schwaab T, Tretter CP, Gibson JJ, Cole BF, Schned AR, Harris R, Fisher JL, Crosby N, Stempkowski LM, Heaney JA, Ernstoff MS.

Prostate. 2006 May 1;66(6):667-74.

PMID:
16425182
37.

Impaired cytolytic activity in peripheral blood T cells from renal cell carcinoma patients.

Crocenzi TS, Tretter CP, Schwaab T, Schned AR, Heaney JA, Cole BF, Fisher JL, Ernstoff MS.

Clin Immunol. 2005 Oct;117(1):6-11.

PMID:
16027041
38.

Images in clinical medicine. Scrotal cancer.

Schwaab T, Nangia AK.

N Engl J Med. 2005 May 12;352(19):2002. No abstract available.

39.

Immunological effects of granulocyte-macrophage colony-stimulating factor and autologous tumor vaccine in patients with renal cell carcinoma.

Schwaab T, Tretter C, Gibson JJ, Cole BF, Schned AR, Harris R, Wallen EM, Fisher JL, Waugh MG, Truman D, Stempkowski LM, Crosby NA, Heaney J, Ernstoff MS.

J Urol. 2004 Mar;171(3):1036-42.

PMID:
14767265
40.

Dendritic Cell Infiltration in Colon Cancer.

Schwaab T, Weiss JE, Schned AR, Barth RJ Jr.

J Immunother (1991). 2001 Mar;24(2):130-137.

PMID:
11449069
41.

Dendritic cell infiltration in colon cancer.

Schwaab T, Weiss JE, Schned AR, Barth RJ Jr.

J Immunother. 2001 Mar-Apr;24(2):130-7.

PMID:
11265770
42.

Phase I pilot trial of the bispecific antibody MDXH210 (anti-Fc gamma RI X anti-HER-2/neu) in patients whose prostate cancer overexpresses HER-2/neu.

Schwaab T, Lewis LD, Cole BF, Deo Y, Fanger MW, Wallace P, Guyre PM, Kaufman PA, Heaney JA, Schned AR, Harris RD, Ernstoff MS.

J Immunother. 2001 Jan-Feb;24(1):79-87.

PMID:
11211151
44.

In vivo description of dendritic cells in human renal cell carcinoma.

Schwaab T, Schned AR, Heaney JA, Cole BF, Atzpodien J, Wittke F, Ernstoff MS.

J Urol. 1999 Aug;162(2):567-73.

PMID:
10411089

Supplemental Content

Loading ...
Support Center